Environmental pathogens, such as Escherichia coli and Streptococcus uberis, are currently the major cause of mastitis within dairy herds. This leads to severe financial losses, lower production rates and deterioration of the general health of the herd. E. coli mastitis is becoming a major threat to high milk-producing dairy herds. This is because of its increasing resistance to antibiotics, rendering antibiotic treatment regimes against E. coli infections mostly ineffective. The aim of this study was to develop a method to select mastitis causing E. coli isolates for the formulation of effective herd specific vaccines. Two methods, namely a genotyping method (Random Amplification of Polymorphic DNA; RAPD) and an antibiogram based method, were used. A dairy farm milking approximately 1000 Holstein cows in the Darling area, Western Cape Province, was selected for this study. The study was conducted over a period of 48 months and mastitis samples were analysed for mastitis pathogens. Antibiogram testing (disk diffusion method) and an in-house developed RAPD analysis method were used to analyse the E. coli isolates. A total of 921 milk samples were analysed from which 181 E. coli isolates were recovered. The number of all other common mastitis pathogens combined was 99 isolates (Streptococcus uberis 18, Streptococcus dysgalactiae 46, Streptococcus agalactiae 1, Staphylococcus epidermidis 21, Arcanobacterium pyogenes 13). All E. coli isolates, except for one, were resistant to at least three antibiotics. Antibiotic variance profiles were also highly erratic. The RAPD analysis revealed high levels of polymorphisms and clear epidemiological trends were observed over time. No similarities in the variance profiles between the antibiotic variance data and phylogenetic data were observed. Formalin inactivated autogenous vaccines were produced containing E. coli isolated from the herd. The vaccines were formulated using the RAPD or antibiogram data of the E. coli isolates. A total of 5 vaccines were formulated using RAPD data (Rvaccines) and one vaccine was formulated using antibiotic variance data (A-vaccine). The RAPD formulated vaccines were more effective than the antibiotic variance formulated vaccine. After each R-vaccination, the number of E. coli mastitis cases declined within the herd. The A-vaccinations seemed to have had no effect, which lead to a rise in E. coli mastitis cases. RAPD analysis on new emerging isolates was able to detect genetic variation from vaccine strains, which in turn facilitated the formulation of new updated vaccines with higher effectiveness than the previous vaccine. Mastitis data prior to and after the vaccination period revealed significant higher incidences of mastitis in the herd than during the vaccination period. This study demonstrated that sufficient sampling practices coupled with a reliable genotyping method, resulted in the formulation of updatable vaccines which were highly effective in controlling E. coli mastitis within the herd. / Thesis (M Environmental Sciences)--North-West University, Potchefstroom Campus, 2012

No description available.

Memoria para optar al Título Profesional de Médico Veterinario / El uso indiscriminado de antimicrobianos en animales de producción es la principal causa del aumento de la resistencia bacteriana, por lo que organizaciones intergubernamentales solicitan disminuir el uso excesivo de estos fármacos. La mastitis es causada principalmente por Escherichia coli en la zona central de Chile y, debido a que su tratamiento se concentra en el uso de antimicrobianos, se ha estudiado Aloe barbadensis Miller (Aloe vera) como una alternativa terapéutica por su efecto antimicrobiano. El objetivo de este trabajo fue evaluar el efecto inhibitorio “in vitro” de A. vera asociado a Ceftiofur en concentraciones menores a su Concentración Mínima Inhibitoria (CMI), frente a E. coli ATCC 25922 y en cepas aisladas de vacas con mastitis clínica. Se utilizó el Método de Macrodilución en Caldo. La CMI fue determinada mediante turbidez y confirmada por recuento de UFC/mL y por espectrofotometría UV-visible. Las cepas de campo fueron sometidas a un estudio de sensibilidad (Kirby Bauer) frente a un panel de antimicrobianos antes de analizar el efecto inhibitorio de A. vera. La CMI de A. vera se determinó en 60 mg/mL. La asociación de A. vera/Ceftiofur no inhibió el crecimiento de E. coli ATCC 25922. Todas las cepas de campo presentaron sensibilidad intermedia o resistencia a al menos un antimicrobiano, pero fueron inhibidas por A. vera. Esto sugiere que A. vera es más efectiva en la inhibición del crecimiento de E. coli en comparación a la asociación y podría presentarse como una alternativa terapéutica frente a mastitis clínicas causadas por E. coli. / Proyecto Fondef IDeA CA12I10008

Memoria para optar al Título Profesional de Médico Veterinario / El uso excesivo de antimicrobianos, debido a la intensificación de los sistemas productivos, ha producido un aumento en la resistencia bacteriana. Debido a esto, diferentes organizaciones intergubernamentales han solicitado el uso racional de estos fármacos en estos sistemas productivos. El mal uso de antimicrobianos se observa en diversas patologías, dentro de las cuales se encuentra la mastitis clínica del ganado lechero, cuyo principal agente etiológico en la zona sur del país es Staphylococcus aureus, resistente a múltiples fármacos. Por este motivo se han estudiado nuevas alternativas terapéuticas, como Aloe vera, por su efecto antimicrobiano. Se evaluaron los efectos inhibitorios de liofilizados de geles de A. vera comercial y extraído de plantas nacionales, asociados a cloxacilina o ceftiofur frente a S. aureus ATCC 29213 mediante el Método de Macrodilución en Caldo. Se determinó su Concentración Mínima Inhibitoria (CMI) mediante turbidez y se confirmó por UFC/mL y absorbancia. Los resultados obtenidos demostraron una disminución de un 87,5% y 75% en las CMI establecidas por el CLSI de ceftiofur y cloxacilina respectivamente. Estos resultados permitirían formular un tratamiento intramamario con esta asociación para las mastitis clínicas causadas por S. aureus. Esto disminuiría la posibilidad de generar resistencia, como también reduciría los periodos de carencia definidos actualmente para estos fármacos. / Proyecto Fondef IDeA 12I10008

Orientador: José Jurandir Fagliari / Coorientador: Ana Maria Centola Vidal / Banca: Paulo Francisco Domingues / Banca: Daniela Gomes Silva / Banca: Kalina Maria de Medeiros Gomes Simplício / Banca: Viviani Gomes / Resumo: O estudo teve como objetivo avaliar as alterações da secreção láctea de cabras com mastite mediante o uso do teste da caneca de fundo escuro, California Mastitis Test (CMT), contagem de células somáticas (CCS) e perfil microbiológico, bem como determinar o perfil bioquímico, em especial de proteínas de fase aguda, do soro sanguíneo e soro lácteo de cabras com mastite clínica ou subclínica, de ocorrência natural. Foram constituídos três grupos experimentais compostos de 30 metades mamárias de cabras sadias, com secreção láctea negativa na prova da caneca de fundo escuro, CMT e no exame microbiológico (grupo controle - G1), 30 metades mamárias com secreção láctea negativa ao teste da caneca de fundo escuro, reação moderada (2+) ou intensa (3+) no CMT e positividade no exame microbiológico (Grupo mastite subclínica - G2) e 12 metades mamárias com secreção láctea positiva na prova da caneca de fundo escuro e no exame microbiológico (grupo mastite clínica - G3). Após antissepsia dos tetos foram colhidas amostras de leite para CCS, cultura microbiológica e determinação do perfil bioquímico do soro lácteo, inclusive o proteinograma mediante fracionamento em gel de poliacrilamida (SDS-PAGE), e amostras de sangue venoso para determinação do perfil bioquímico sérico. A contagem automática de células somáticas (CCS) e por contagem microscopia direta foi maior nas amostras de secreção láctea das cabras com mastite subclínica (G2: 4.500.000 células/mL e 20.830.000 células/mL, respectivamente) e com mastite clínica (G3: 7.500.000 células/mL e 39.100.000 células/mL, respectivamente). Staphylococcus aureus, Staphylococcus coagulase negativa (SCN), Staphylococcus coagulase positiva (SCP), Corynebacterium spp. e Streptococcus spp. foram os microrganismos isolados nas amostras de leite das cabras do G2 e G3. As amostras de soro lácteo das cabras do G2 e G3 apresentaram maiores atividades das enzimas... / Abstract: The study aimed to evaluate the changes in milk from goats with mastitis by using the strip cup test, California Mastitis Test (CMT), somatic cell count (SCC) and microbiological profile as well as to determine the biochemical profile, especially acute phase proteins, in blood serum and whey from goats with naturally occurring clinical or subclinical mastitis. Three experimental groups were formed by 30 mammary glands from healthy goats with milk samples negative to strip cup test, CMT and microbiological examination (control group - G1); 30 mammary glands with milk samples negative to strip cup test but with moderate (2+) or intense (3+) reaction in CMT and microbiological examination (group with subclinical mastitis - G2), and 12 mammary glands with positive results to strip cup test and microbiological examination (group with clinical mastitis - G3). After asepsis of the teats milk samples were collected for SCC, microbiological culture, and to determine the biochemical profile in whey, including proteinogram by fractionation in poliacrylamide gel electrophoresis (SDS-PAGE). At the same time, blood samples were obtained to determine the serum biochemical profile. Automatic and microscopic methods were higher in milk samples from goats with subclinical mastits (G2: 4,500.000 cells/mL e 20,830,000 cells/mL, respectively) e with clinical mastitis (G3: 7,500,000 células/mL e 39,100,000 cells/mL, respectively). Staphylococcus aureus, Coagulase-negative Staphylococcus (CNS), Coagulase-positive Staphylococcus (CPS), Corynebaterium spp. and Streptococcus spp. were the microorganisms isolated in milk samples from goats of G2 and G3. Whey samples from goats of G2 and G3 showed higher activity of alkaline phosphatase (G2: 122 U/L and G3: 207 U/L) and gamma-glutamyltransferase (G2: 483 U/L and G3: 571 U / L), and higher concentrations of albumin (G2: 0.18 g/dL and G3: 0.29 g/dL), total protein (G2: 1.50 g/dL and G3: 1.67 g/dL), chlorides ... / Doutor

No description available.

Mastitis is the most prevalent and major cause of economic losses in dairy farms. Bovine mastitis caused by strains of <i>S. aureus</i> is a major economically important disease affecting the dairy industry worldwide. <i>S. aureus</i> is one of the most common udder pathogens that cause either clinical or sub-clinical mammary gland infections. Different treatment regimes have failed to cure <i>S. aureus</i> intramammary infections. Most mastitis vaccination strategies have focused on the enhancement of systemic humoral immunity rather than strengthening local intramammary immunity. Vaccines aimed at enhancing intramammary immunity of dairy cows against <i>S. aureus</i> mastitis have had limited success. Commercially available vaccines show various degrees of success and work in research laboratories with experimental vaccines suggest that in part, the failure of these vaccines lies in the limited antigenic repertoire contained in the vaccine formulations. Moreover, not only does variation in the antigenic composition but also presence of capsular polysaccharide in most pathogenic strains and decreased activity of immune effectors in milk affect the success of vaccines. In addition to these, the ability of <i>S. aureus</i> to attach and internalize into mammary epithelial cells, enables bacteria to escape from the effect of immunity and antibiotics by being hidden in the intracellular niche and thereby causing chronic recurrent intramammary infection. <i>S. aureus</i> also has the ability to become electron-transport-defective and to form slow-growing small colonies that are non haemolytic and less virulent. These small colony variants might hide from the immune surveillance in the intracellular area and revert to the parental strain causing chronic recurrent infections. If immunization targets antigenic molecules that are conserved throughout all pathogenic strains, even the small colony variants can be controlled since the immune system will clear the parental strain which causes lethal infection. Thus, immunization trials should focus on conserved immunogenic antigen molecules among pathogenic strains formulated with an adjuvant and delivered by a route of immunization to induce maximum stimulation of the immune system. Moreover, immunization should focus on inducing Th1 responses, which is protective against <i>S. aureus</i> mastitis. It has been reported that proteins with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity might be used as such antigens to induce protection against parasitic and microbial infections. Previous study in our laboratory on mastitis-causing streptococci indicates that GapC proteins of <i>S. uberis</i> and <i>S. dysgalactiae</i> have potential as vaccine antigens to protect dairy cows against mastitis caused by environmental streptococci. Two conserved cell wall associated proteins with iii glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, GapB and GapC have been identified from <i>S. aureus</i> isolates from bovine intramammary infections. The overall goal of this study was to improve our understanding on intramammary immunity using the GapC and GapB proteins of <i>S. aureus</i> as model antigens for mastitis and to determine the regulation of expression of <i>gapB</i> and <i>gapC</i> genes and their roles in the pathogenesis of bovine <i>S. aureus</i> mastitis. We hypothesized that strengthening local intramammary immunity using GapB and GapC proteins of <i>S. aureus</i> as antigens will protect against bovine <i>S. aureus</i> mastitis. To test this hypothesis we took the approach of using the <i>gapB</i> and <i>gapC</i> genes and constructed plasmids encoding GapB, GapC and GapB::GapC (GapC/B) chimeric proteins. We set six objectives to test our hypothesis using these proteins to enhance the intramammary immunity. In aim 1 we constructed plasmids encoding the GapB, GapC proteins and also constructed a chimeric gene encoding the GapC and GapB proteins as a single entity (GapC/B chimera) as the basis for a multivalent vaccine. In this objective the humoral and cellular immune responses to GapC/B were compared to the responses to the individual proteins alone or in combination in C57 BL/6 mice. Our results showed that the GapC/B protein elicited strong humoral and cellular immune responses as judged by the levels of total IgG, IgG1, IgG2a, IL-4 and IFN-ã secretion and lymphocyte proliferation. These results strongly suggest the potential of this chimeric protein as a target for vaccine production to control mastitis caused by <i>S. aureus</i>. In aim 2 we continued our studies on GapC/B by testing the effects of DNA vaccination with plasmids encoding the individual gapB and gapC genes as well as the gapC/B protein gene with or without a boost with the recombinant proteins. The results showed that DNA vaccination alone was unable to elicit a significant humoral response and barely able to elicit a detectable cell-mediated response to the recombinant antigens but subsequent immunization with the proteins elicited an excellent response. In addition, we found that DNA vaccination using a plasmid encoding the GapC/B chimera followed by a boost with the same protein, although successful, is less effective than priming with plasmids encoding GapB or GapC followed by a boost with the individual antigens. In aim 3 we optimized immune responses in cows by comparing route of vaccination (subcutaneous versus intradermal), site of vaccination (locally at the area drained by the supramammary lymph node versus distantly at area drained by parotid lymph node. Our results showed that both subcutaneous and intradermal immunizations with the GapC/B protein at the area drained by the supramammary and parotid lymph nodes resulted in significantly increased serum and milk titers of total IgG, IgG1, IgG2, iv and IgA in all vaccinated groups as compared to placebo. The anti-GapC/B IgG1 serum and milk titers were significantly higher in all vaccinated group as compared to the placebo group. These results indicated that vaccination at the area drained by the supramammary lymph node resulted in better immune responses. In aim 4 we tested different formulations of the GapC/B antigen with adjuvants such as PCPP, CpG, PCPP + CpG and VSA-3. We found that the VSA-3 formulation induced the best immune responses in cows. In this objective we also monitored immune responses longitudinally over one lactation cycle to determine the duration of immune responses by measuring IgG, IgG1, IgG2, and IgA on monthly blood and milk samples. We found that the duration of immune responses was about four months. In aim 5 we tested the role of GapC in the virulence of <i>S. aureus</i> mastitis using the <i>S. aureus</i> wild type strain RN6390 and its isogenic GapC mutant strain H330. Our results from both in vitro adhesion and invasion assays on MAC- T cells and in vivo infection of ovine mammary glands showed that GapC is an important virulence factor in <i>S. aureus</i> mastitis. In aim 6 we examined the role of sar and agr loci on the expression of <i>gapC</i> and <i>gapB</i> genes by qRT- PCR using <i>S. aureus</i> RN6390 and its isogenic mutants defective in agrA, sarA and sar/agr (double mutant) at exponential and stationary phases of growth. Our results showed that both <i>gapB</i> and <i>gapC</i> expression were down regulated in the mutant strains, indicating that the expression of the <i>gapB</i> and <i>gapC</i> genes is controlled by the universal virulence gene regulators, agr and sar. We also checked the role of environmental factors such as pH, growth media, and oxygen tension on the expression of <i>gapB</i> and <i>gapC</i> using q-RT-PCR. Our results showed that the expression of <i>gapB</i> and <i>gapC</i> genes in different strains of <i>S. aureus</i> was not consistent under the above-mentioned environmental conditions.

Mastitis is the most prevalent and major cause of economic losses in dairy farms. Bovine mastitis caused by strains of <i>S. aureus</i> is a major economically important disease affecting the dairy industry worldwide. <i>S. aureus</i> is one of the most common udder pathogens that cause either clinical or sub-clinical mammary gland infections. Different treatment regimes have failed to cure <i>S. aureus</i> intramammary infections. Most mastitis vaccination strategies have focused on the enhancement of systemic humoral immunity rather than strengthening local intramammary immunity. Vaccines aimed at enhancing intramammary immunity of dairy cows against <i>S. aureus</i> mastitis have had limited success. Commercially available vaccines show various degrees of success and work in research laboratories with experimental vaccines suggest that in part, the failure of these vaccines lies in the limited antigenic repertoire contained in the vaccine formulations. Moreover, not only does variation in the antigenic composition but also presence of capsular polysaccharide in most pathogenic strains and decreased activity of immune effectors in milk affect the success of vaccines. In addition to these, the ability of <i>S. aureus</i> to attach and internalize into mammary epithelial cells, enables bacteria to escape from the effect of immunity and antibiotics by being hidden in the intracellular niche and thereby causing chronic recurrent intramammary infection. <i>S. aureus</i> also has the ability to become electron-transport-defective and to form slow-growing small colonies that are non haemolytic and less virulent. These small colony variants might hide from the immune surveillance in the intracellular area and revert to the parental strain causing chronic recurrent infections. If immunization targets antigenic molecules that are conserved throughout all pathogenic strains, even the small colony variants can be controlled since the immune system will clear the parental strain which causes lethal infection. Thus, immunization trials should focus on conserved immunogenic antigen molecules among pathogenic strains formulated with an adjuvant and delivered by a route of immunization to induce maximum stimulation of the immune system. Moreover, immunization should focus on inducing Th1 responses, which is protective against <i>S. aureus</i> mastitis. It has been reported that proteins with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity might be used as such antigens to induce protection against parasitic and microbial infections. Previous study in our laboratory on mastitis-causing streptococci indicates that GapC proteins of <i>S. uberis</i> and <i>S. dysgalactiae</i> have potential as vaccine antigens to protect dairy cows against mastitis caused by environmental streptococci. Two conserved cell wall associated proteins with iii glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity, GapB and GapC have been identified from <i>S. aureus</i> isolates from bovine intramammary infections. The overall goal of this study was to improve our understanding on intramammary immunity using the GapC and GapB proteins of <i>S. aureus</i> as model antigens for mastitis and to determine the regulation of expression of <i>gapB</i> and <i>gapC</i> genes and their roles in the pathogenesis of bovine <i>S. aureus</i> mastitis. We hypothesized that strengthening local intramammary immunity using GapB and GapC proteins of <i>S. aureus</i> as antigens will protect against bovine <i>S. aureus</i> mastitis. To test this hypothesis we took the approach of using the <i>gapB</i> and <i>gapC</i> genes and constructed plasmids encoding GapB, GapC and GapB::GapC (GapC/B) chimeric proteins. We set six objectives to test our hypothesis using these proteins to enhance the intramammary immunity. In aim 1 we constructed plasmids encoding the GapB, GapC proteins and also constructed a chimeric gene encoding the GapC and GapB proteins as a single entity (GapC/B chimera) as the basis for a multivalent vaccine. In this objective the humoral and cellular immune responses to GapC/B were compared to the responses to the individual proteins alone or in combination in C57 BL/6 mice. Our results showed that the GapC/B protein elicited strong humoral and cellular immune responses as judged by the levels of total IgG, IgG1, IgG2a, IL-4 and IFN-ã secretion and lymphocyte proliferation. These results strongly suggest the potential of this chimeric protein as a target for vaccine production to control mastitis caused by <i>S. aureus</i>. In aim 2 we continued our studies on GapC/B by testing the effects of DNA vaccination with plasmids encoding the individual gapB and gapC genes as well as the gapC/B protein gene with or without a boost with the recombinant proteins. The results showed that DNA vaccination alone was unable to elicit a significant humoral response and barely able to elicit a detectable cell-mediated response to the recombinant antigens but subsequent immunization with the proteins elicited an excellent response. In addition, we found that DNA vaccination using a plasmid encoding the GapC/B chimera followed by a boost with the same protein, although successful, is less effective than priming with plasmids encoding GapB or GapC followed by a boost with the individual antigens. In aim 3 we optimized immune responses in cows by comparing route of vaccination (subcutaneous versus intradermal), site of vaccination (locally at the area drained by the supramammary lymph node versus distantly at area drained by parotid lymph node. Our results showed that both subcutaneous and intradermal immunizations with the GapC/B protein at the area drained by the supramammary and parotid lymph nodes resulted in significantly increased serum and milk titers of total IgG, IgG1, IgG2, iv and IgA in all vaccinated groups as compared to placebo. The anti-GapC/B IgG1 serum and milk titers were significantly higher in all vaccinated group as compared to the placebo group. These results indicated that vaccination at the area drained by the supramammary lymph node resulted in better immune responses. In aim 4 we tested different formulations of the GapC/B antigen with adjuvants such as PCPP, CpG, PCPP + CpG and VSA-3. We found that the VSA-3 formulation induced the best immune responses in cows. In this objective we also monitored immune responses longitudinally over one lactation cycle to determine the duration of immune responses by measuring IgG, IgG1, IgG2, and IgA on monthly blood and milk samples. We found that the duration of immune responses was about four months. In aim 5 we tested the role of GapC in the virulence of <i>S. aureus</i> mastitis using the <i>S. aureus</i> wild type strain RN6390 and its isogenic GapC mutant strain H330. Our results from both in vitro adhesion and invasion assays on MAC- T cells and in vivo infection of ovine mammary glands showed that GapC is an important virulence factor in <i>S. aureus</i> mastitis. In aim 6 we examined the role of sar and agr loci on the expression of <i>gapC</i> and <i>gapB</i> genes by qRT- PCR using <i>S. aureus</i> RN6390 and its isogenic mutants defective in agrA, sarA and sar/agr (double mutant) at exponential and stationary phases of growth. Our results showed that both <i>gapB</i> and <i>gapC</i> expression were down regulated in the mutant strains, indicating that the expression of the <i>gapB</i> and <i>gapC</i> genes is controlled by the universal virulence gene regulators, agr and sar. We also checked the role of environmental factors such as pH, growth media, and oxygen tension on the expression of <i>gapB</i> and <i>gapC</i> using q-RT-PCR. Our results showed that the expression of <i>gapB</i> and <i>gapC</i> genes in different strains of <i>S. aureus</i> was not consistent under the above-mentioned environmental conditions.

Dissertation (Ph.D.)--Auburn University, / Abstract. Vita. Includes bibliographic references (p.81-103).

Thesis (Ph. D.)--West Virginia University, 2003. / Title from document title page. Document formatted into pages; contains v, 95 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references (p. 80-94).